{"schema_version":"secwatch.filing_event.v1","accession":"0001720580-26-000006","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.998591+00:00","generated_at":"2026-05-15T13:40:13.479323+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adicet Bio reports Q4 2025 net loss $30.5M; Phase 1 prula-cel enrollment momentum; cash $158.5M","bullets":["Net loss Q4 2025: $30.5M ($2.94 per diluted share) compared to $28.7M ($5.06) in Q4 2024.","Full-year 2025 net loss $116.8M ($16.95 per share) vs $117.1M ($21.33) in 2024.","Cash, equivalents & investments $158.5M at Dec 31, 2025; expected to fund ops into H2 2027.","Phase 1 prula-cel autoimmune enrollment ahead; next update H1 2026; pivotal study H2 2026 subject to FDA.","ADI-212 regulatory filing for mCRPC expected Q3 2026; Phase 1 enrollment Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001720580-26-000006","json":"https://secwatch.observer/filing/0001720580-26-000006.json","markdown":"https://secwatch.observer/filing/0001720580-26-000006.md","text":"https://secwatch.observer/filing/0001720580-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000006/0001720580-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000006/acet-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:40:13.479323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}